公开(公告)号：US20240269220A1

公开(公告)日：2024-08-15

申请号：US18566993

申请日：2022-03-24

Applicant: Chang Gung University ,  Chang Gung University of Science and Technology

Inventor： Tsong-Long HWANG ,  Yu-Chia CHANG ,  Wu-Dai-Yu JIANG

IPC: A61K36/898 ,  A61K31/05 ,  A61K31/085 ,  A61K31/09

CPC classification number: A61K36/898 ,  A61K31/05 ,  A61K31/085 ,  A61K31/09

Abstract: Disclosed herein is a method of treating diseases and/or disorders associated with the dysregulated activation and recruitment of neutrophils. The method includes administering to a subject in need thereof an effective amount of an extract of Bletilla formosana. The Bletilla formosana extract includes, at least, compounds of 3,3′-dihydroxy-5-methoxybibenzyl (Batatacin III), 9,10-dihydro-1-[(4-hydroxyphenyl)methyl]-4-methoxy-2,7-phenanthrenediol (Orchidble), 3′,5-dimethoxy-3-hydroxybibenzyl (BF8-4-2), 3,5-dimethoxy-3′-hydroxybibenzyl (BF8-4-3) and 3-hydroxy-5-methoxybibenzyl (BF8-4-4).

公开(公告)号：US12132448B2

公开(公告)日：2024-10-29

申请号：US17372569

申请日：2021-07-12

Applicant: Chang Gung University

Inventor： Cher-Ming Tan ,  Vimal Kant Pandey

IPC: H03F1/10 ,  G01T1/17 ,  H01L29/20 ,  H03F3/193

CPC classification number: H03F1/10 ,  G01T1/17 ,  H01L29/2003 ,  H03F3/193 ,  H03F2200/451

Abstract: The present invention relates to a gallium nitride transimpedance amplifier, as an essential electronic circuit in the proton beam therapy. Because gallium nitride is more tolerant to the secondary radiation generated during the proton beam therapy, it has high reliability and increases the reliability of the overall system.

公开(公告)号：US20240307471A1

公开(公告)日：2024-09-19

申请号：US18465109

申请日：2023-09-11

Applicant: Chang Gung University

Inventor： Pei-Wen Hsieh ,  Tsong-Long Hwang ,  Yu-Ling Huang

IPC: A61K36/185 ,  A61P31/14

CPC classification number: A61K36/185 ,  A61P31/14 ,  A61K2236/331 ,  A61K2236/39

Abstract: A method against coronavirus infection includes administering to a subject in need thereof a pharmaceutical composition containing a water-extracted product of Melastoma malabathricum root.

公开(公告)号：US12028031B2

公开(公告)日：2024-07-02

申请号：US17503467

申请日：2021-10-18

Applicant: Chang Gung University

Inventor： Cher-Ming Tan ,  Vimal Kant Pandey

IPC: H03F3/45

CPC classification number: H03F3/45076

Abstract: The present invention is gallium nitride based operational amplifier because reliability and performance of the gallium nitride is better than the silicon counterpart in radiation environment. The operational amplifier includes four stages, first stage is dual input balanced output differential amplifier, second stage is dual input unbalanced differential amplifier, third stage is buffer stage to couple second and fourth stage, and fourth stage is cascaded common source amplifier with degeneration. A capacitor coupled between second and third stage is to enhance the stability of operational amplifier.

公开(公告)号：US20240123017A1

公开(公告)日：2024-04-18

申请号：US18482014

申请日：2023-10-05

Applicant: Chang Gung University of Science and Technology

Inventor： Tsong-Long Hwang ,  Yu-Chia Chang

IPC: A61K36/898 ,  A61P17/02

CPC classification number: A61K36/898 ,  A61P17/02

Abstract: A method for promoting chronic wound healing is provided, including administering an effective amount of Bletilla formosana (Hayata) Schltr. extract to a subject in need thereof, wherein the effective amount of Bletilla formosana (Hayata) Schltr. extract is 0.01 mg/kg-body weight to 100 mg/kg-body weight, and wherein the chronic wound including diabetic wound and Diabetic Foot Ulcer.

公开(公告)号：US11761044B2

公开(公告)日：2023-09-19

申请号：US16451942

申请日：2019-06-25

Applicant: Chang Gung University

Inventor： Hsin-Pai Li ,  Cheng-Lung Hsu

IPC: C12Q1/68 ,  C12Q1/6886 ,  G16H50/30 ,  G16B20/10 ,  G16B40/10

CPC classification number: C12Q1/6886 ,  G16B20/10 ,  G16B40/10 ,  G16H50/30 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The disclosure provides a method for evaluating whether an individual with cancer is suitable for being administered with anti-cancer drugs. Wherein the anti-cancer drug is a CDK inhibitor. The method includes the following steps: (1) detecting a copy number of a first gene and a copy number of a second gene from an in vitro sample of the individual with the cancer to obtain a copy number variation (CNV) of the first gene and a copy number variation (CNV) of the second gene; (2) calculating a copy number variation ratio (CNV ratio) between the copy number variation (CNV) of the first gene and the copy number variation (CNV) of the second gene, wherein the first gene encodes a cyclin and the second gene encodes a cyclin dependent kinase inhibitor (CDKN); and (3) determining whether the individual with the cancer is suitable for being administered with the CDK inhibitor according to the CNV ratio.

公开(公告)号：US11517246B2

公开(公告)日：2022-12-06

申请号：US15923919

申请日：2018-03-16

Applicant: Chang Gung University ,  Chang Gung Memorial Hospital, Linkou ,  Chang Gung Medical Foundation Chang Gung Memorial Hospital at Keelung

Inventor： Jiun-Jie Wang ,  Yi-Hsin Weng ,  Shu-Hang Ng ,  Jur-Shan Cheng ,  Yi-Ming Wu ,  Yao-Liang Chen ,  Wey-Yil Lin ,  Chin-Song Lu ,  Wen-Chuin Hsu ,  Chia-Ling Chen ,  Yi-Chun Chen ,  Sung-Han Lin ,  Chih-Chien Tsai

IPC: A61B5/00 ,  A61B5/055 ,  G06T7/00

Abstract: Disclosed herein is a method for diagnosing a neurological disorder based on at least one magnetic resonance imaging (MRI) image. The method includes identifying brain image regions that contain a respective portion of diffusion index values of at least one diffusion index. For each of the brain image regions, a characteristic parameter based on the respective portion of the diffusion index values is calculated. a diagnoses is then made for the brain using one of predetermined categories of the neurological disorder by performing classification on a combination of the characteristic parameters via a classifier.

公开(公告)号：US11452754B2

公开(公告)日：2022-09-27

申请号：US16785880

申请日：2020-02-10

Applicant: Taipei Chang Gung Memorial Hospital ,  Chang Gung University

Inventor： Yi-Hong Wu ,  Yueh Hsiang Huang ,  Jong-Hwei Su Pang

IPC: A61K36/71 ,  A61K36/25 ,  A61K36/076 ,  A61P3/06 ,  A61P3/10 ,  A61P3/04 ,  A61K36/894

Abstract: Pharmaceutical compositions containing a combination of rhizoma coptidis and a herbal composition comprises at least one herb selected from the group consisting of Radix Ginseng, Poria, Rhizoma Atractylodis macrocephalae, Semen Lablab album, Rhizoma Dioscoreae, Embryo Nelumbinis, Radix Platycodonis, Semen Coicis, Fructus Amomi, Fructus Jujubae and Radix Glycyrrhizae are disclosed. Methods of treating diseases by administering an effective amount of the pharmaceutical composition are also provided.

公开(公告)号：US11363968B2

公开(公告)日：2022-06-21

申请号：US15837872

申请日：2017-12-11

Applicant: Chang Gung University

Inventor： Ya-Ju Chang ,  Jiunn-Woei Liaw ,  Hung-Bin Chen

IPC: A61B5/11 ,  A61B5/103 ,  A61B5/00

Abstract: A center of pressure (CoP) based control system includes a sensing device and an electronic device connected to the sensing device. The sensing device includes sensors each of which continuously measures force exerted thereon by a subject and generates a sense signal based on a result of the measurement. The electronic device is connected to the sensing device, and receives the sense signals from the respective sensors, generates CoP data associated with a CoP trajectory based on the sense signals, determines whether a turning point exists in the CoP trajectory, generates an indication signal based on a result of the determination, and generates a control signal based on a direction of one of displacements of the CoP.

公开(公告)号：US11351172B2

公开(公告)日：2022-06-07

申请号：US16793275

申请日：2020-02-18

Applicant: Chang Gung University

Inventor： Tsong-Long Hwang ,  Po-Jen Chen

IPC: A61K31/519 ,  A61P11/00

Abstract: The invention provides a pharmaceutical composition for treating phosphodiesterase 4-mediated (PDE4-mediated) disease in a patient and inhibition of phosphodiesterase 4 (PDE4) activity. The pharmaceutical composition includes an effective amount of Ribociclib and a pharmaceutically acceptable carrier. The invention further provides a use of the pharmaceutical composition for treating PDE4-mediated disease in a patient. The application of the pharmaceutical composition of the present invention and use thereof are advantageous for inhibiting of PDE4 activity and thus treating a PDE4-mediated disease.